SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented data from the Company’s autoimmunity program with its investigational drug candidate TRIOLEX™ (HE3286) at the 6th International Congress on Autoimmunity, held in Porto, Portugal, September 10th to the 14th. Dr. Christopher L. Reading, Chief Scientific Officer at Hollis-Eden Pharmaceuticals and Dr. Dominick L. Auci, Director of Allergy, Autoimmunity and Inflammation, presented the data during a dedicated plenary session. Hollis-Eden conducted the session to further inform the scientific community on the potential role of the Company’s new class of adrenal steroid hormones in autoimmune and other inflammatory disorders. Data presented included positive findings generated to date from extensive research in preclinical models of numerous autoimmune conditions, as well as preliminary findings from the Company’s ongoing Phase I/II dose ranging clinical trial with TRIOLEX in patients with active, mild-to-moderate ulcerative colitis (UC).
